Browse drugs

…gh-dose corticosteroids and methotrexate, and later switched to adalimumab due to steroid toxicity and abnormal liver function. Adalimumab…

…CT00661661 and ORAL Sequel) assessed time to discontinuation of tofacitinib treatment.Results At baseline, female patients had similar DAS2…

…ted with systemic immunosuppression, including a combination of methotrexate (n=6), adalimumab (n=5), mycophenolate (n=2), oral corticostero…

…oprine proved ineffective in maintaining clinical remission and Infliximab was initiated. Due to ongoing symptoms her IFX dose was increas…

… receiving biologic therapy at the time of the audit, including infliximab in 47, adalimumab in 13, ustekinumab in 2, and vedolizumab in 1…

… M, Green Z, Morris K. OC4 Discontinuation of premedication for infliximab infusions is well-tolerated, without adverse events, and cost-s…

…b 44.3%, Adalimumab 27.9%, Vedolizumab 13.1%, Ustekinumab 9.8%, Golimumab 3.3% and Risankizumab 1.6%.The mean [±SD] gestational age at tr…

…ommon recent drugs were adalimumab, infliximab, ustekinumab and vedolizumab. There were no significant differences between groups in potent…

…e primary outcome was the association between time to first AT (Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab or Tofacitinib…

…uired minor adjustment. Templates of moderate duration included ustekinumab, vedolizumab, and adalimumab counselling, with completion times…

…A man in his 40s who takes adalimumab for Crohn’s disease presented with a 1-day history of fever, he…

…le therapeutic options, anti-TNFα monoclonal antibodies such as infliximab (IFX) and adalimumab (ADA) are widely used in moderate-to-sever…